These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26466344)

  • 21. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
    Aljenedil S; Ruel I; Watters K; Genest J
    J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.
    Cuevas A; Fernández C; Ferrada L; Zambrano T; Rosales A; Saavedra N; Salazar LA
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):292-7. PubMed ID: 26408409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A; Taylor RR; Mamotte CD
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels.
    de Keyser CE; Becker ML; Hofman A; Lous JJ; Uitterlinden AG; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2015 Mar; 25(3):134-42. PubMed ID: 25602530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
    Polisecki E; Muallem H; Maeda N; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Westendorp RG; de Craen AJ; Buckley BM; Ordovas JM; Schaefer EJ;
    Atherosclerosis; 2008 Sep; 200(1):109-14. PubMed ID: 18261733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
    Medina MW
    Discov Med; 2010 Jun; 9(49):495-9. PubMed ID: 20587337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
    Karayan L; Qiu S; Betard C; Dufour R; Roederer G; Minnich A; Davignon J; Genest J
    Arterioscler Thromb; 1994 Aug; 14(8):1258-63. PubMed ID: 8049186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
    Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
    J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy.
    Kirac D; Bayam E; Dagdelen M; Gezmis H; Sarikaya S; Pala S; Altunok EC; Genc E
    Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):43-48. PubMed ID: 29096742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia.
    Alsehli AM; Rukh G; Clemensson LE; Ciuculete DM; Tan X; Al-Sabri MH; Williams MJ; Benedict C; Schiöth HB
    Front Biosci (Landmark Ed); 2021 Dec; 26(12):1453-1463. PubMed ID: 34994160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
    Kajinami K; Yagi K; Higashikata T; Inazu A; Koizumi J; Mabuchi H
    Am J Cardiol; 1998 Jul; 82(1):113-7. PubMed ID: 9671018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.
    Chang XL; Tan L; Tan MS; Wang HF; Tan CC; Zhang W; Zheng ZJ; Kong LL; Wang ZX; Jiang T; Yu JT; Tan L
    Oncotarget; 2016 Apr; 7(16):22746-51. PubMed ID: 27009838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.